Cyberbiosecurity for Biopharmaceutical Products
نویسندگان
چکیده
منابع مشابه
Development of Test Method for Pharmaceutical and BioPharmaceutical Products
The statement that "The Process Is the Product." was based on the understanding that the main production agent-living organismsproduce large quantities of chemically similar material (e.g., proteins) that must undergo a variety of separation steps that can select the greatest yield of the highest purity of a desired molecular entity from the cellular-derived milieu. The separation processes use...
متن کاملAdvanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical products.
Mass spectrometry has already become an indispensable tool in the analytical armamentarium of the biopharmaceutical industry, although its current uses are limited to characterization of covalent structure of recombinant protein drugs. However, the scope of applications of mass spectrometry-based methods is beginning to expand to include characterization of the higher order structure and dynami...
متن کاملMammalian cell protein expression for biopharmaceutical production.
Mammalian cell expression has become the dominant recombinant protein production system for clinical applications because of its capacity for post-translational modification and human protein-like molecular structure assembly. While expression and production have been fully developed and Chinese hamster ovary cells are used for the majority of products both on the market and in clinical develop...
متن کاملViral clearance for biopharmaceutical downstream processes
2015 Viral clearance studies are mandated prior to entering clinical trials and for commercial launch of biopharmaceuticals. These studies are a key component of risk mitigation to reduce the potential for iatrogenic transmission of pathogenic viruses. This paper reviews regulatory guidance and practical strategies for designing viral clearance studies. Essential elements of a developmental pha...
متن کاملA Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
UNLABELLED Regulatory monographs in Europe and the United States require drug products for parenteral administration to be "practically free" or "essentially free" of visible particles, respectively. Both terms have been used interchangeably and acknowledge the probabilistic nature of visual particle inspection. The probability of seeing a particle in a drug product container varies according t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Bioengineering and Biotechnology
سال: 2019
ISSN: 2296-4185
DOI: 10.3389/fbioe.2019.00116